DJ Results of Annual General Meeting
Arix Bioscience PLC (ARIX)
Results of Annual General Meeting
14-Jun-2021 / 14:55 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience Plc
Results of Annual General Meeting
LONDON, 14 June 2021: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global venture capital
company focused on investing and building breakthrough biotech companies, today announces that its Annual General
Meeting (the "Meeting") was held today, Monday, 14 June 2021, at 14.00 BST. At the Meeting, the ordinary and special
resolutions set out in the Notice of the Annual General Meeting dated 18 May 2021 (the "Notice of AGM"), were proposed
and passed by way of a poll. Resolutions 1 to 10 were passed as ordinary resolutions. Resolutions 11 to 14 were passed
as special resolutions.
Full details of the poll results are set out below and will also be available on the Company's website.
VOTES TOTAL % of VOTES
No RESOLUTION VOTES FOR % AGAINST % VOTES ISC WITHHELD
VOTED
To receive the Directors' Report and the
1 accounts of the Company for the year ended 61,517,202 92.76% 4,800,657 7.24% 66,317,859 50.32 2,783
31 December 2020
2 To approve the Directors' Remuneration 58,196,535 92.34% 4,825,953 7.66% 63,022,488 47.82 3,298,154
Report
3 To re-elect Giles Kerr as a Director 61,344,286 92.51% 4,964,902 7.49% 66,309,188 50.31 11,454
4 To elect Peregrine Moncreiffe as a Director 60,271,773 92.55% 4,855,144 7.45% 65,126,917 49.42 1,193,725
5 To elect Maureen O'Connell as a Director 58,841,750 90.36% 6,274,013 9.64% 65,115,763 49.41 1,204,879
6 To elect Isaac Kohlberg as a Director 58,842,050 90.35% 6,285,167 9.65% 65,127,217 49.42 1,193,425
7 To elect Robert Lyne as a Director 60,072,787 90.59% 6,236,701 9.41% 66,309,488 50.31 11,154
8 To appoint BDO LLP as auditors of the 61,500,167 92.74% 4,817,701 7.26% 66,317,868 50.32 2,774
Company
To authorise the Audit and Risk Committee
9 of the Company to fix the remuneration of 61,516,153 92.76% 4,804,189 7.24% 66,320,342 50.32 300
the auditors
10 To authorise the Directors to allot shares 61,019,094 92.01% 5,297,239 7.99% 66,316,333 50.32 4,309
11 Authority to disapply statutory pre- 59,364,402 89.52% 6,951,931 10.48% 66,316,333 50.32 4,309
emption rights*
12 Additional authority to disapply statutory 59,363,555 89.52% 6,952,778 10.48% 66,316,333 50.32 4,309
pre- emption rights*
13 To authorise the Company to purchase its 61,478,596 92.71% 4,836,857 7.29% 66,315,453 50.32 5,189
own shares*
Authority to call a general meeting, other
14 than an annual general meeting, on not less 61,517,295 92.76% 4,803,047 7.24% 66,320,342 50.32 300
than 14 clear days' notice*
*Special resolutions
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 18 May 2021, which is available on Arix investor relations website.
A replay of the presentation and the Meeting will be available via webcast shortly after the event on the Company's investor relations website at: https://arixbioscience.com/investor-relations/events-presentations
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com -----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071 Category Code: RAG TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 111187 EQS News ID: 1207766 End of Announcement EQS News Service =------------------------------------------------------------------------------------ Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1207766&application_name=news
(END) Dow Jones Newswires
June 14, 2021 09:55 ET (13:55 GMT)
